Prestige Consumer Healthcare Inc. (NYSE:PBH) Shares Bought by Natixis Advisors LLC

Natixis Advisors LLC grew its position in Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) by 1,335.1% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 209,246 shares of the company's stock after acquiring an additional 194,665 shares during the quarter. Natixis Advisors LLC owned approximately 0.42% of Prestige Consumer Healthcare worth $16,340,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also made changes to their positions in the company. Allspring Global Investments Holdings LLC boosted its holdings in Prestige Consumer Healthcare by 3.1% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 1,624,501 shares of the company's stock worth $126,274,000 after purchasing an additional 49,331 shares during the period. Geode Capital Management LLC grew its position in shares of Prestige Consumer Healthcare by 4.0% during the 3rd quarter. Geode Capital Management LLC now owns 1,326,794 shares of the company's stock valued at $95,678,000 after buying an additional 50,961 shares during the last quarter. Congress Asset Management Co. raised its stake in Prestige Consumer Healthcare by 5.0% during the fourth quarter. Congress Asset Management Co. now owns 908,742 shares of the company's stock worth $70,964,000 after acquiring an additional 43,619 shares during the period. Boston Trust Walden Corp lifted its holdings in Prestige Consumer Healthcare by 43.5% in the fourth quarter. Boston Trust Walden Corp now owns 831,627 shares of the company's stock worth $64,942,000 after acquiring an additional 252,089 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its stake in Prestige Consumer Healthcare by 5.6% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 636,020 shares of the company's stock valued at $49,667,000 after acquiring an additional 33,844 shares during the period. 99.95% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Insider Buying and Selling

In related news, SVP Mary Beth Fritz sold 1,678 shares of the firm's stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $90.00, for a total transaction of $151,020.00. Following the completion of the transaction, the senior vice president now owns 17,157 shares of the company's stock, valued at $1,544,130. This trade represents a 8.91 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 1.60% of the stock is owned by corporate insiders.

Prestige Consumer Healthcare Stock Performance

Shares of PBH traded down $0.24 during trading hours on Friday, reaching $84.12. 640,928 shares of the company's stock traded hands, compared to its average volume of 258,829. The firm has a market capitalization of $4.17 billion, a price-to-earnings ratio of 19.70, a P/E/G ratio of 2.69 and a beta of 0.46. The business's fifty day simple moving average is $82.46 and its two-hundred day simple moving average is $78.59. Prestige Consumer Healthcare Inc. has a twelve month low of $62.35 and a twelve month high of $90.04. The company has a debt-to-equity ratio of 0.56, a current ratio of 3.68 and a quick ratio of 2.20.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last released its earnings results on Thursday, February 6th. The company reported $1.22 EPS for the quarter, beating the consensus estimate of $1.18 by $0.04. Prestige Consumer Healthcare had a net margin of 19.13% and a return on equity of 12.36%. Analysts predict that Prestige Consumer Healthcare Inc. will post 4.5 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on the company. Oppenheimer increased their price target on Prestige Consumer Healthcare from $87.00 to $93.00 and gave the stock an "outperform" rating in a research report on Thursday, February 13th. Royal Bank of Canada raised their target price on Prestige Consumer Healthcare from $96.00 to $97.00 and gave the company a "sector perform" rating in a research note on Friday. Canaccord Genuity Group boosted their price target on shares of Prestige Consumer Healthcare from $93.00 to $100.00 and gave the company a "buy" rating in a report on Friday, February 7th. Sidoti cut shares of Prestige Consumer Healthcare from a "buy" rating to a "neutral" rating and set a $90.00 price objective on the stock. in a report on Monday, December 9th. Finally, StockNews.com raised shares of Prestige Consumer Healthcare from a "hold" rating to a "buy" rating in a research note on Tuesday. Three investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $93.33.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.